Stock Research for CRME

CRME

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

CRME Stock Chart & Research Data

The CRME chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CRME chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


CRME Due diligence Resources & Stock Charts

The CRME stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View CRME Detailed Price Forecast - CNN Money CNN View CRME Detailed Summary - Google Finance
Yahoo View CRME Detailed Summary - Yahoo! Finance Zacks View CRME Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View CRME Trends & Analysis - Trade-Ideas Barrons View CRME Major Holders - Barrons
NASDAQ View CRME Call Transcripts - NASDAQ Seeking View CRME Breaking News & Analysis - Seeking Alpha
Spotlight View CRME Annual Report - CompanySpotlight.com OTC Report View CRME OTC Short Report - OTCShortReport.com
TradeKing View CRME Fundamentals - TradeKing Charts View CRME SEC Filings - Bar Chart
WSJ View Historical Prices for CRME - The WSJ Morningstar View Performance/Total Return for CRME - Morningstar
MarketWatch View the Analyst Estimates for CRME - MarketWatch CNBC View the Earnings History for CRME - CNBC
StockMarketWatch View the CRME Earnings - StockMarketWatch MacroAxis View CRME Buy or Sell Recommendations - MacroAxis
Bullish View the CRME Bullish Patterns - American Bulls Short Pains View CRME Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View CRME Stock Mentions - StockTwits PennyStocks View CRME Stock Mentions - PennyStockTweets
Twitter View CRME Stock Mentions - Twitter Invest Hub View CRME Investment Forum News - Investor Hub
Yahoo View CRME Stock Mentions - Yahoo! Message Board Seeking Alpha View CRME Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for CRME - SECform4.com Insider Cow View Insider Transactions for CRME - Insider Cow
CNBC View CRME Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for CRME - OTC Markets
Yahoo View Insider Transactions for CRME - Yahoo! Finance NASDAQ View Institutional Holdings for CRME - NASDAQ


Stock Charts

FinViz View CRME Stock Insight & Charts - FinViz.com StockCharts View CRME Investment Charts - StockCharts.com
BarChart View CRME Stock Overview & Charts - BarChart Trading View View CRME User Generated Charts - Trading View




Latest Financial News for CRME


Correvio Pharma Corp, Formerly Cardiome Pharma Corp, Announces Stock Ticker Symbol Change to CORV
Posted on Thursday May 17, 2018

Correvio Pharma Corp, Formerly Cardiome Pharma Corp, Announces Stock Ticker Symbol Change to CORV


Correvio Announces Enrollment of First Patient in Phase 3 Study Evaluating Brinavess® in China
Posted on Thursday May 17, 2018

VANCOUVER , May 17, 2018 /CNW/ - Correvio Pharma Corp. (NASDAQ: CRME / TSX: COM), formerly Cardiome Pharma Corp., today announced that its partner Eddingpharm has enrolled the first patient in a randomized, double-blind, placebo-controlled, Phase 3 clinical study evaluating Brinavess® versus placebo in patients with recent onset atrial fibrillation (AF).  Approximately 240 patients are expected to be enrolled at an estimated 30 clinical trial sites in China . The primary objective of the study is to demonstrate the effectiveness of Brinavess in the conversion of recent onset AF to sinus rhythm, compared to placebo. Secondary objectives include assessment of the safety and tolerability of Brinavess, time to conversion of AF to sinus rhythm and pharmacokinetics, among others.


Cardiome: 1Q Earnings Snapshot
Posted on Tuesday May 15, 2018

The Vancouver, British Columbia-based company said it had a loss of 24 cents per share. The cardiovascular drug maker posted revenue of $6.5 million in the period. In the final minutes of trading on Tuesday, ...


Correvio Reports First Quarter 2018 Financial Results
Posted on Tuesday May 15, 2018

Correvio Reports First Quarter 2018 Financial Results


Stock Market & Investing Books

Enter a stock symbol to view the stock details.